Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS G12D Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of Vemurafenib and Sorafenib in patients KRAS G12D mutated pancreatic cancer who have progressed on standard of care chemotherapy.
General Information
NCT#: NCT05068752
Study ID: HRI-Vemurafenib-Sorafenib
Trial Phase: Phase II
Trial Sponsor: HonorHealth Research Institute
Therapies Used in This Trial: Sorafenib, Vemurafenib